Benzolactam compounds as protein kinase inhibitors
US11001575B1 · kind B1 · utility
3Cited by
2References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 2019 |
| Grant date | May 11, 2021 |
| Priority date | — |
| Expiry date | Aug 15, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula (0): The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.